published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsCOVIT-TRIAL, 2022 0.54 [0.22; 1.34] VERU-111, 2022 0.30 [0.14; 0.64] 0.38[0.22; 0.68]COVIT-TRIAL, 2022, VERU-111, 202220%404moderatenot evaluable death D28detailed resultsCAN-COVID, 2020 0.67 [0.30; 1.50] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19] COVIT-TRIAL, 2022 0.89 [0.45; 1.75] FACCT Trial, 2021 0.69 [0.28; 1.68] GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Krolewiecki, 2020 0.49 [0.01; 26.05] Pandit, 2021 0.95 [0.02; 50.33] PLACID, 2020 1.04 [0.66; 1.63] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Silva, 2021 0.46 [0.03; 8.02] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.72[0.57; 0.90]CAN-COVID, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, COVIT-TRIAL, 2022, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Krolewiecki, 2020, Pandit, 2021, PLACID, 2020, RAPID (Sholzberg), 2021, Shashi Bhushan, 2021, Silva, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021150%4,942moderatelow death or transfer to ICUdetailed resultsPLACID, 2020 1.07 [0.73; 1.57] RAPID (Sholzberg), 2021 0.70 [0.44; 1.12] 0.89[0.59; 1.34]PLACID, 2020, RAPID (Sholzberg), 2021246%929seriousnot evaluable deathsdetailed resultsAbd-Elsalam, 2021 0.74 [0.16; 3.42] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20] CAN-COVID, 2020 0.67 [0.30; 1.50] Cantini, 2020 0.06 [0.00; 1.21] Capra, 2020 0.04 [0.00; 0.33] ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04] COVIT-TRIAL, 2022 0.89 [0.45; 1.75] Dabbous HM, 2020 0.51 [0.02; 15.41] FACCT Trial, 2021 0.96 [0.44; 2.08] Fu, 2020 1.00 [0.02; 51.66] Glorial F, 2020 1.11 [0.05; 25.91] GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] Hung et al., 2020 0.47 [0.01; 24.30] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Khamis, 2020 0.83 [0.23; 2.96] Khan, 2020 0.12 [0.02; 0.97] Kirti, 2021 0.12 [0.01; 2.36] Krolewiecki, 2020 0.49 [0.01; 26.05] Libster, 2020 0.50 [0.09; 2.71] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] Lopes (BRACE CORONA), 2021 0.97 [0.38; 2.50] Lopes MIF, 2020 1.06 [0.02; 56.61] Majmundar, 2020 0.53 [0.22; 1.29] Murugesan, 2022 1.00 [0.02; 51.41] NCT04342650, 2020 0.95 [0.02; 48.42] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] NCT04542694, 2020 1.00 [0.02; 50.90] Pandit, 2021 0.95 [0.02; 50.33] PLACID, 2020 1.04 [0.66; 1.63] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] Ren, 2020 1.00 [0.02; 55.80] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Rocco, 2020 1.02 [0.02; 51.70] SAVE-MORE, 2021 0.45 [0.20; 0.99] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Shenoy S, 2021 1.32 [0.58; 2.99] Solaymani-Dodaran, 2021 1.22 [0.66; 2.26] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] Udwadia, 2020 0.50 [0.02; 15.03] Yeramaneni, 2020 1.64 [1.14; 2.36] Zhaowei Chen, 2020 1.00 [0.02; 52.04] 0.80[0.69; 0.94]Abd-Elsalam, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, CAN-COVID, 2020, Cantini, 2020, Capra, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, COVIT-TRIAL, 2022, Dabbous HM, 2020, FACCT Trial, 2021, Fu, 2020, Glorial F, 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Hung et al., 2020, I-TECH (Lim), 2022, Khamis, 2020, Khan, 2020, Kirti, 2021, Krolewiecki, 2020, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopes (BRACE CORONA), 2021, Lopes MIF, 2020, Majmundar, 2020, Murugesan, 2022, NCT04342650, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, PLACID, 2020, RAPID (Sholzberg), 2021, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, SAVE-MORE, 2021, Shashi Bhushan, 2021, Shenoy S, 2021, Solaymani-Dodaran, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Udwadia, 2020, Yeramaneni, 2020, Zhaowei Chen, 20204911%15,407moderatecritical deaths (time to event analysis only)detailed resultsCapra, 2020 0.04 [0.00; 0.33] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] 0.51[0.24; 1.06]Capra, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, LIVE-AIR (Temesgen), 2021540%1,620moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92] ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] ELACOI (Standard of care), 2020 0.86 [0.06; 11.36] I-TECH (Lim), 2022 1.25 [0.87; 1.80] Kamran, 2020 0.95 [0.32; 2.78] Li T, 2020 0.48 [0.01; 27.44] Libster, 2020 0.52 [0.29; 0.94] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] PLACID, 2020 1.04 [0.54; 1.99] RAPID (Sholzberg), 2021 0.69 [0.43; 1.10] Ravichandran, 2021 0.02 [0.00; 0.36] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95] Rocco, 2020 1.02 [0.29; 3.58] SAVE-MORE, 2021 0.36 [0.26; 0.50] Zhaowei Chen, 2020 0.11 [0.01; 2.19] 0.71[0.52; 0.98]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, I-TECH (Lim), 2022, Kamran, 2020, Li T, 2020, Libster, 2020, NCT04523831 (Mahmud), 2020, PLACID, 2020, RAPID (Sholzberg), 2021, Ravichandran, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, SAVE-MORE, 2021, Zhaowei Chen, 20201863%4,293moderatelow clinical improvementdetailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] CAN-COVID, 2020 1.39 [0.76; 2.54] Chachar, 2020 1.19 [0.38; 3.72] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] Ghandehari, 2020 1.31 [1.00; 1.71] Glorial F, 2020 0.90 [0.04; 20.92] GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] Hung et al., 2020 3.92 [1.66; 9.24] Khan, 2020 8.27 [1.03; 66.34] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] NCT04542694, 2020 2.10 [1.04; 4.24] Rocco, 2020 0.81 [0.52; 1.27] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Shashi Bhushan, 2021 0.68 [0.21; 2.20] Tang, 2020 1.01 [0.59; 1.74] Udwadia, 2020 1.75 [1.10; 2.79] 1.25[1.03; 1.52]AVIFAVIR, 2020, CAN-COVID, 2020, Chachar, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Ghandehari, 2020, Glorial F, 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, Khan, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Rocco, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Tang, 2020, Udwadia, 20201960%4,699moderatelow clinical improvement (14-day)detailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] Pandit, 2021 8.77 [0.94; 81.67] Ruzhentsova T, 2020 1.28 [1.05; 1.56] Shashi Bhushan, 2021 0.68 [0.21; 2.20] 1.22[1.00; 1.49]AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 20211032%2,913moderatelow clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57] GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] Ruzhentsova T, 2020 1.11 [0.96; 1.29] Udwadia, 2020 1.75 [1.10; 2.79] 1.34[1.10; 1.62]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020546%3,321moderateserious clinical improvement (7-day)detailed resultsChachar, 2020 1.19 [0.38; 3.72] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35] GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] Kirti, 2021 0.90 [0.77; 1.06] NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] NCT04542694, 2020 2.10 [1.04; 4.24] Rocco, 2020 0.81 [0.52; 1.27] Ruzhentsova T, 2020 1.50 [1.02; 2.21] Shashi Bhushan, 2021 1.91 [1.03; 3.53] 1.25[1.02; 1.55]Chachar, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Rocco, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 20211164%3,019moderatecritical clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] Hung et al., 2020 3.92 [1.66; 9.24] Min, 2020 1.09 [0.58; 2.05] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Shenoy S, 2021 0.99 [0.77; 1.28] Shinkai, 2021 1.40 [0.91; 2.15] Solaymani-Dodaran, 2021 0.94 [0.75; 1.17] Tang, 2020 1.01 [0.59; 1.74] Udwadia, 2020 1.75 [1.10; 2.79] 1.17[1.00; 1.37]FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, Min, 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Shenoy S, 2021, Shinkai, 2021, Solaymani-Dodaran, 2021, Tang, 2020, Udwadia, 20201364%3,767moderatecritical death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07] CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52] LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98] RAPID (Sholzberg), 2021 0.59 [0.34; 1.02] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] 0.75[0.63; 0.88]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, CORIMUNO-ANA-1, 2021, LIVE-AIR (Temesgen), 2021, RAPID (Sholzberg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202150%4,009moderatenot evaluable hospital dischargedetailed resultsCantini, 2020 23.94 [10.77; 53.20] FACCT Trial, 2021 0.88 [0.64; 1.21] Kirti, 2021 1.20 [0.73; 1.98] Li T, 2020 10.00 [1.03; 97.50] Majmundar, 2020 3.65 [2.20; 6.06] RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04] Shenoy S, 2021 1.06 [0.85; 1.32] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] Udwadia, 2020 1.41 [0.97; 2.03] 2.09[1.29; 3.40]Cantini, 2020, FACCT Trial, 2021, Kirti, 2021, Li T, 2020, Majmundar, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shenoy S, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Udwadia, 2020990%3,032moderateserious hospitalizationdetailed resultsHolubar M, 2021 0.12 [0.01; 2.26] Jagannathan, 2020 1.00 [0.14; 7.34] 0.46[0.06; 3.45]Holubar M, 2021, Jagannathan, 2020228%269lownot evaluable mechanical ventilationdetailed resultsAbd-Elsalam, 2021 1.00 [0.20; 5.11] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] I-TECH (Lim), 2022 0.41 [0.13; 1.30] Khan, 2020 0.12 [0.06; 0.25] Kirti, 2021 0.20 [0.00; 8.69] Li (Methylprednisolone, Shanghai cohort), 2020 0.24 [0.07; 0.87] Li T, 2020 0.40 [0.04; 3.90] Lopes (BRACE CORONA), 2021 1.25 [0.76; 2.06] Majmundar, 2020 0.31 [0.14; 0.69] PLACID, 2020 0.99 [0.54; 1.81] RAPID (Sholzberg), 2021 0.70 [0.32; 1.54] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] SAVE-MORE, 2021 0.47 [0.03; 7.48] Solaymani-Dodaran, 2021 1.62 [0.85; 3.08] Udwadia, 2020 0.06 [0.01; 0.83] Yeramaneni, 2020 2.53 [1.42; 4.52] 0.64[0.40; 1.03]Abd-Elsalam, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Khan, 2020, Kirti, 2021, Li (Methylprednisolone, Shanghai cohort), 2020, Li T, 2020, Lopes (BRACE CORONA), 2021, Majmundar, 2020, PLACID, 2020, RAPID (Sholzberg), 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, SAVE-MORE, 2021, Solaymani-Dodaran, 2021, Udwadia, 2020, Yeramaneni, 20202074%6,732moderatecritical mechanical ventilation (time to event analysis only)detailed resultsUdwadia, 2020 0.06 [0.01; 0.83] 0.06[0.01; 0.83]Udwadia, 202010%14NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] ELACOI (Standard of care), 2020 0.18 [0.01; 3.99] Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28] Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88] 1.82[0.95; 3.51]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021439%450moderatenot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] ELACOI (Standard of care), 2020 0.08 [0.00; 1.71] Ren, 2020 19.00 [0.85; 422.73] Zhaowei Chen, 2020 3.43 [1.10; 10.70] 0.98[0.09; 10.24]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Ren, 2020, Zhaowei Chen, 2020472%128moderatenot evaluable viral clearance detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Chaccour, 2020 0.92 [0.77; 1.09] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Espitia-Hernandez, 2020 715.00 [12.94; 39513.71] HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] Holubar M, 2021 0.76 [0.48; 1.20] Hung et al., 2020 4.37 [1.86; 10.25] Jagannathan, 2020 0.81 [0.56; 1.18] Min, 2020 1.53 [0.81; 2.88] NCT04542694, 2020 13.03 [2.96; 57.24] Pandit, 2021 2.33 [0.55; 9.83] Rastogi, 2020 6.33 [1.54; 26.00] Ravichandran, 2021 1.71 [0.80; 3.64] Ren, 2020 28.50 [1.27; 640.66] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Shashi Bhushan, 2021 2.77 [1.44; 5.32] Tang, 2020 0.85 [0.58; 1.23] Udwadia, 2020 1.37 [0.94; 1.98] 1.56[1.19; 2.06]AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Espitia-Hernandez, 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Hung et al., 2020, Jagannathan, 2020, Min, 2020, NCT04542694, 2020, Pandit, 2021, Rastogi, 2020, Ravichandran, 2021, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Tang, 2020, Udwadia, 20202172%1,980moderatecritical viral clearance (time to event analysis only)detailed resultsAhmed, 2020 4.10 [1.12; 14.99] Holubar M, 2021 0.76 [0.48; 1.20] Hung et al., 2020 4.37 [1.86; 10.25] Jagannathan, 2020 0.81 [0.56; 1.18] Min, 2020 1.53 [0.81; 2.88] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Tang, 2020 0.85 [0.58; 1.23] Udwadia, 2020 1.37 [0.94; 1.98] 1.25[0.91; 1.72]Ahmed, 2020, Holubar M, 2021, Hung et al., 2020, Jagannathan, 2020, Min, 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020871%976moderateserious viral clearance by day 14detailed resultsAhmed, 2020 4.10 [1.12; 14.99] AVIFAVIR, 2020 3.08 [0.62; 15.39] Bukhari, 2021 0.91 [0.02; 46.94] ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Li T, 2020 1.00 [0.03; 34.67] Pandit, 2021 10.23 [1.12; 93.35] Ruzhentsova T, 2020 0.99 [0.93; 1.06] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 1.04[0.23; 4.74]Ahmed, 2020, AVIFAVIR, 2020, Bukhari, 2021, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 20211093%1,883moderatelow viral clearance by day 7detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Bukhari, 2021 11.56 [3.53; 37.91] Chaccour, 2020 0.92 [0.77; 1.09] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89] ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] ELACOI (Standard of care), 2020 0.67 [0.10; 4.58] Kirti, 2021 0.80 [0.43; 1.50] Pandit, 2021 2.33 [0.55; 9.83] PLACID, 2020 1.20 [1.00; 1.44] Ravichandran, 2021 1.71 [0.80; 3.64] Ren, 2020 28.50 [1.27; 640.66] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] Ruzhentsova T, 2020 1.05 [0.92; 1.20] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 1.33[1.05; 1.68]AVIFAVIR, 2020, Bukhari, 2021, Chaccour, 2020, Dabbous HM, 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirti, 2021, Pandit, 2021, PLACID, 2020, Ravichandran, 2021, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shashi Bhushan, 20211567%1,548moderatecritical ICU admissiondetailed resultsCantini, 2020 0.04 [0.01; 0.32] COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] FACCT Trial, 2021 1.42 [0.79; 2.55] I-TECH (Lim), 2022 0.78 [0.27; 2.23] Khamis, 2020 1.03 [0.35; 3.03] Khan, 2020 0.10 [0.01; 0.77] Kirti, 2021 0.90 [0.30; 2.70] Libster, 2020 0.33 [0.07; 1.58] Majmundar, 2020 0.16 [0.07; 0.35] RAPID (Sholzberg), 2021 0.79 [0.48; 1.30] Rocco, 2020 4.11 [0.18; 91.83] Solaymani-Dodaran, 2021 1.23 [0.70; 2.18] 0.59[0.35; 1.01]Cantini, 2020, COL-COVID (Pascual-Figal), 2021, FACCT Trial, 2021, I-TECH (Lim), 2022, Khamis, 2020, Khan, 2020, Kirti, 2021, Libster, 2020, Majmundar, 2020, RAPID (Sholzberg), 2021, Rocco, 2020, Solaymani-Dodaran, 20211270%3,082moderatelow recoverydetailed resultsCrippa (CANDIDATE), 2021 0.54 [0.15; 1.94] GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03] GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.01[0.82; 1.25]Crippa (CANDIDATE), 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020456%1,284moderatenot evaluable severe COVID-19 occurrencedetailed resultsELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27] 0.30[0.07; 1.27]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable serious adverse eventsdetailed resultsCAN-COVID, 2020 0.73 [0.45; 1.19] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] Hung et al., 2020 0.23 [0.01; 7.12] Jagannathan, 2020 1.00 [0.14; 7.34] Krolewiecki, 2020 1.00 [0.03; 31.59] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] NCT04542694, 2020 6.15 [0.30; 124.49] Pandit, 2021 0.95 [0.02; 50.33] Ren, 2020 1.00 [0.02; 55.80] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] Ruzhentsova T, 2020 2.06 [0.09; 46.40] Shinkai, 2021 2.80 [0.14; 56.95] Udwadia, 2020 1.03 [0.02; 52.48] 0.74[0.53; 1.02]CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, Jagannathan, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020170%3,722moderatelow acute kidney injury detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18] 1.18[0.44; 3.18]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78] COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01] Holubar M, 2021 2.07 [0.89; 4.83] Jagannathan, 2020 1.33 [0.63; 2.78] Krolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] NCT04542694, 2020 1.00 [0.54; 1.85] Pandit, 2021 1.68 [0.47; 5.97] Ravichandran, 2021 1.04 [0.02; 52.86] Ren, 2020 0.12 [0.01; 2.86] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47] Ruzhentsova T, 2020 1.90 [0.96; 3.80] Shinkai, 2021 19.54 [7.77; 49.11] Spoorthi, 2020 2.19 [0.61; 7.81] Udwadia, 2020 6.36 [2.43; 16.65] 1.85[1.37; 2.48]Chaccour, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Jagannathan, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ravichandran, 2021, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shinkai, 2021, Spoorthi, 2020, Udwadia, 20202261%4,019moderatelow arrhythmiadetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69] 2.24[0.23; 21.69]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable elevated liver enzymesdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64] 3.48[1.40; 8.64]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable long QTdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50] 9.79[1.27; 75.50]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%174NAnot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67] 1.80[0.88; 3.67]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,227NAnot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86] 1.35[0.47; 3.86]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable serious adverse events (SAE), anydetailed resultsGS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79] 0.50[0.32; 0.79]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable Thromboembolic eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55] 0.89[0.31; 2.55]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-30 23:45 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290